Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
NCT ID: NCT00749697
Last Updated: 2008-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
10 participants
INTERVENTIONAL
2008-05-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPECT scan
SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* histological confirmation of the differentiated thyroid carcinoma available
* WHO performance score 0-2
* metastatic sites lung and/or bone and/or nodal (radiologically measurable disease \> 1 cm)
* life expectancy \> 6 months
* patient has undergone total/near total thyroidectomy
* no past history of sensitivity/reaction to 1311
Exclusion Criteria
* received chemotherapy or radiotherapy in 6 weeks
* pregnant or breast feeding patients
* iodine contrast injection in last 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Marsden NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Royal Marsden NHS Foundation Trust
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Kate Newbold
Role: PRINCIPAL_INVESTIGATOR
Royal Marsden NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Marsden NHS Foundation Trust
London, Sutton, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dr Kate Newbold
Role: primary
Dr Prasad Dandekar
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCR3047
Identifier Type: -
Identifier Source: org_study_id